Corporate Overview

In this Connect to Frankfurt session, Séverine Fagète, VP, Cell Line Development Services at Selexis (Geneva, Switzerland), and Brandon Brino (Durham, USA), Process Development Scientist and Group Leader at KBI Biopharma, present an overview of a streamlined process for the production of bispecific molecules.  

iotechnology Progress:Volume 38, Issue 2, March/April 2022  

Rashmi P. Bhangale, Rui Ye, Thomas B. Lindsey, Leslie S. Wolfe.

 
KBI's Downstream Process Development Team at our Durham, North Carolina location had their work published in the March/April 2022 issue (Volume 38, Issue 2) of Biotechnology Progress.

KBI was the first CDMO to implement the 2000L scale single-use bioreactor. We deliver cGMP drug substance supplying first-in-human to commercial.

Biopharmaceuticals are a significant growth area for the pharmaceutical industry, as these therapeutics can address unmet medical needs through novel mechanisms of action. A wide range of biopharmaceuticals is currently in clinical development, including monoclonal antibodies (mAbs), recombinant proteins, and Fc fusion proteins. These biomolecule-based therapies can offer significant therapeutic benefits and have numerous applications in oncology, immunology, neurology, and inflammation-based disorders, among others.

KBI’s extensive analytical capabilities help our clients develop lasting solutions to analytical challenges faced during the development of biologics.

Our unique expertise enables us to express “difficult-to-refold” products. Using scalable, high-density microbial fermentation, our clients benefit from shorter development at each phase and subsequently lower cost.

KBI has substantial expertise and knowledge in process and analytical development, manufacturing, and regulatory aspects of cellular therapies and maintains strong relationships with the US FDA and Health Canada.

A breakthrough approach to bispecific production via streamlined workflow; cell line development to GMP manufacturing.

Experience The Power Of KBI And Selexis In Geneva.

One premier location for cell line development, process development, and manufacturing. Built for end-to-end services, and globally known for tackling some of the most challenging biologics projects.


That's the power you have with KBI and Selexis in Geneva. That's the power of together.

One premier location for cell line development, process development, and manufacturing. Built for end-to-end services, and globally known for tackling some of the most challenging biologics projects.   

That's the power you have with KBI and Selexis in Geneva. That's the power of together.  

This webinar will demonstrate a breakthrough platform approach that encompasses the efficient production of bispecific molecules in an integrated, streamlined way, from CLD (cell line development) to cGMP manufacturing. The leverageable integrated workflow from Selexis and KBI Biopharma generates high quality clinical bulk drug substances under accelerated timelines.

Did you enjoy this session? If so, you might like to visit our Connect to Frankfurt platform, where you can browse our collection of 30+ on-demand webinars and learn about our upcoming CPHI Frankfurt event, taking place 1-3 November in Frankfurt, Germany.

Bringing together the global supply chain under one roof, CPHI Frankfurt puts you at the heart of pharma. Can’t attend in person? You can access many of the event offerings online! Browse our exhibitor list, arrange meetings, view on-site content and network – all from home.


Click here to register

Contract laboratories are time constrained which affects provider and client. This is especially notable for Cell Based Testing Teams, where the assays vary due to growth condition variability and the plotting of titration curves to accurately measure any effect on the targeted mechanism of action. To overcome this, the Cell Based Assay Team at KBI uses a modeling tool to predict the cellular response to an agonist or antagonist.